130
Participants
Start Date
November 30, 2015
Primary Completion Date
April 25, 2023
Study Completion Date
June 2, 2023
surufatinib
orally once daily (QD) in patients with advanced solid tumor.
Mount Sinai Hospital, New York
Memorial Sloan Kettering Cancer Center, New York
Virginia Cancer Specialists, PC, Fairfax
Florida Cancer Specialists, Sarasota
Tennessee Oncology, Nashville
Mary Crowley Cancer Research Center, Dallas
Baylor Charles A. Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Rocky Mountain Cancer Center, Denver
SCRI at HealthONE, Denver
City of Hope Comprehensive Cancer Center, Los Angeles
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Lead Sponsor
Hutchmed
INDUSTRY